What are the indications for selpercatinib (Retevmo) in the treatment of non-small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

For patients with RET fusion-positive NSCLC, selpercatinib (Retevmo) is indicated.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!